Entry |
|
Name |
Mutation-activated KIT to PI3K signaling pathway
|
Definition |
KIT* -> PI3K -> PIP3 -> AKT -| BAD |
Expanded |
3815v1 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -| 572 |
Class |
|
Type |
Variant
|
Pathway |
|
Disease |
|
Gene |
3815 | KIT; KIT proto-oncogene receptor tyrosine kinase |
5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
207 | AKT1; AKT serine/threonine kinase 1 |
208 | AKT2; AKT serine/threonine kinase 2 |
10000 | AKT3; AKT serine/threonine kinase 3 |
572 | BAD; BCL2 associated agonist of cell death |
|
Variant |
3815v1 (KIT*) KIT kinase domain mutation
|
Metabolite |
C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
Reference |
|
Authors |
Masson K, Ronnstrand L |
Title |
Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. |
Journal |
|
Reference |
|
Authors |
Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. |
Title |
Normal and oncogenic forms of the receptor tyrosine kinase kit. |
Journal |
|
Reference |
|
Authors |
Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H. |
Title |
The molecular pathogenesis of acute myeloid leukemia. |
Journal |
|
LinkDB |
|